

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

(10) International Publication Number
WO 02/102789 A1

(51) International Patent Classification⁷: C07D 317/52, 317/50, 263/56, A61K 31/36, 31/4184, A61P 31/00, 31/04, 31/06, 31/08, 31/10, 39/00

(74) Agent: GRIFFITH HACK; 509 St Kilda Road, Melbourne, Victoria 3004 (AU).

(21) International Application Number: PCT/AU02/00783

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 14 June 2002 (14.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2001/117033 18 June 2001 (18.06.2001) RU

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): BIODIEM LTD [AU/AU]; Level 10, Atrium Building, 459 Collins Street, Melbourne, Victoria 3000 (AU).

Published:


- with international search report
- with amended claims

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DENISENKO, Peter, Prokofievich [RU/RU]; App 35, 3 Kliuchevaya St, 195221 St Petersburg (RU). SAPRONOV, Nikolay, Sergeevich [RU/RU]; App 76, 47 Blukhera, Prospect, 195067 St Petersburg (RU). TARASENKO, Alexander, Alexandrovich [RU/RU]; App 49, 11 Rubenshtaina St, 191002 St Petersburg (RU).

(54) Title: ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS



WO 02/102789 A1

(57) Abstract: The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R₁ to R₅ are either the same or different and selected from hydrogen or a non-deleterious substituent; and R₆ and R₇ are either the same or different and selected from hydrogen and a non-deleterious substituent or one of R₆ and R₇ are absent when there is a double bond present, pharmaceutically acceptable salts or derivatives, pro-drugs, tautomers and/or isomers thereof. The present invention also relates to a method for protecting a subject from radiation damage, a method of cancer radiotherapy and use as an antimicrobial or radioprotective agent of the compound of formula (I) defined above. Some of the compounds of formula (I) are novel and are also described in the present invention, together with pharmaceutical or veterinary compositions containing them.

- 1 -

ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS

This invention relates to compounds which have antimicrobial and radioprotective activity. In particular,
5 the invention relates to substituted nitrostyrene compounds which have activity against a wide spectrum of organisms including bacteria, fungi and protozoa. The compounds of the invention also have the ability to provide protection from radiation damage.

10

BACKGROUND OF THE INVENTION

All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any
15 reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art
20 publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.

Bacterial, fungal and protozoal pathogens are
25 responsible for a very wide variety of infections, ranging from minor respiratory ailments to fulminant systemic infections and chronic illnesses. Food poisoning caused by organisms such as *Salmonella* or *Campylobacter* is common, and is often associated with endemic infection in livestock
30 or poultry raised using intensive animal husbandry techniques.

Despite the wide availability of antibiotics, control of infection is difficult, and many organisms have the ability to develop resistance. Many microorganisms
35 cause problems which have hitherto proved to be quite intractable, such as multi-drug resistant *Staphylococcus aureus* infection in hospitals, drug-resistant *Enterococcus*

- 2 -

infections, bacterial, fungal and protozoal infection in HIV patients, tuberculosis, and malaria and other endemic infections in underdeveloped countries.


Currently there are only very few agents which
5 have a wide spectrum of activity against pathogens of bacterial, fungal and protozoal origin. Antibiotics are the most widely used agents in the fight against pathogenic microorganisms. However, most antibiotics have narrow specificity. Even broad spectrum antibacterial antibiotics
10 are not very effective against fungi and protozoa. Most antibiotics belong to a restricted range of classes of compounds; although improved semi-synthetic derivatives of these have developed, only a few new antibiotic compound classes have become available in the last twenty years.

15 The choice of agents for protection of living organisms against radioactive radiation is also quite limited. Among the radiation protectors the most effective are sulphur-containing compounds (Kuna, 1989). For example, cystamine is approved for use as a radiation-
20 protective agent (Vladimirov et al, 1989). The index of protection of this preparation does not exceed 1.45, and has the disadvantage that it causes diarrhoea. Another known radiation-protective preparation is mercamine (β -mercaptopoethylamine) (Mashkovskiy, 1986).

25 This has a low therapeutic index, short period of action (0.5-1 h), and short duration of radiation protecting activity (15-30 min).

It is known that β -nitrostyrene and some of its derivatives demonstrate biological, and partly fungicidal
30 activity (Foyer, 1973). Russian Patent No. 2145215 showed that certain derivatives of arylnitroalkenes have antimicrobial, antifungal, antiprotozoal activity, and are able to provide protection from radiation damage. These compounds have the following formula

- 3 -



5

in which R_1' is H or CH_3 ; and
 R_2' and R_3' are the same or different and are selected from H, OCH_3 , OH, NO_2 and $(CH_3)_2N$.


The activities of these compounds are 10 satisfactory, but there is a need for low cost, low-toxicity agents with a wide spectrum of antimicrobial activities.

We have now found that certain substituted nitrostyrene compounds have excellent activity against very 15 wide spectrum of organisms, including bacteria, fungi and protozoa and also have the ability to provide protection from radiation damage.

SUMMARY OF THE INVENTION

The invention provides a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula I:

25



I

30 in which

X and Y are either the same or different and selected from a heteroatom;

35

is a double or single bond depending on the heteroatoms X and Y;

R_1 to R_5 are either the same or different and selected from hydrogen or a non-deleterious substituent;

- 4 -

and

R₆ and R₇ are either the same or different and selected from hydrogen and a non-deleterious substituent or one of R₆ and R₇ are absent when there is a double bond 5 present,

pharmaceutically acceptable salts or derivatives, pro-drugs, tautomers and/or isomers thereof.

The invention also provides use of the compound of formula I in the manufacture of a medicament for the 10 treatment and/or prophylaxis of a microbial infection.

The invention further provides use of the compound of formula I for the treatment and/or prophylaxis of a microbial infection.

The invention still further provides a method for 15 protecting a subject from radiation damage which comprises administering an effective amount of the compound of formula I to a subject in need thereof.

In another aspect, the invention provides a method of cancer radiotherapy which comprises administering 20 to a subject in need of such therapy an effective amount of the compound of formula I and subjecting the locus of a tumour in the subject to a radiation source.

In a further aspect, the invention provides use 25 of the compound of formula I as an antimicrobial or radioprotective agent.

Preferably X and Y are either the same or different and selected from O and N, more preferably both X and Y are oxygen.

Preferably R₁ and R₂ are either the same or 30 different and selected from hydrogen, hydroxy, halogen or optionally substituted C₁₋₆ alkyl.

R₃ to R₅ are preferably either the same or different and selected from hydrogen, hydroxy, halogen, nitro, C₁₋₆ alkoxy or optionally substituted C₁₋₆ alkyl.

35 Preferably halogen is chlorine or bromine.

The E isomer of the compounds of formula I is preferred.


- 5 -

Particularly preferred are compounds of the formula I in which X, Y, ~~Z~~, R₆ and R₇ are as defined above; R₁ and R₂ are either the same or different and selected from hydrogen, hydroxy, Cl, Br and C₁₋₄ alkyl; and R₃ to R₅ are either the same or different and selected from hydrogen, hydroxy, Cl, Br, nitro, C₁₋₄ alkoxy or C₁₋₄ alkyl.

5

Specific examples of the compounds of the present invention are as follows:


(1) X and Y are O, R₁ is methyl and R₂ and R₃ are
10 hydrogen (3,4-methylenedioxy-β-methyl-β-nitrostyrene)



15

1

(2) X and Y are O and R₁ to R₃ are hydrogen
20 (3,4-methylenedioxy-β-nitrostyrene)




25

2

(3) X is N, Y is NH, R₁ is methyl and R₂ and R₃ are hydrogen (benzimidazole-5-β-nitropropylene)

30



3


35

(4) X is N, Y is NH, R₁ is hydrogen, R₂ is

- 6 -


methyl and R₃ is absent (2-methyl
benzimidazole-5-β-nitroethylene)

5



4

(5) X is O, Y is N, R₁ and R₂ are hydrogen and R₃
10 is absent (benzoxazole-5-β-nitroethylene)




15

5

(6) X is N, Y is O, R₁ and R₂ are methyl and R₃
is absent (2-methyl benzoxazole-5-β-
nitropropylene)

20




6

25

Some of the compounds of the formula I are novel
per se.

Accordingly, the invention provides a compound of
formula Ia:

30



35

Ia

in which X, Y, and R₁ to R₇ are as defined in


- 7 -

formula I above,

with the provisos that when both X and Y are O and R₂ to R₇ are hydrogen, then R₁ is not hydrogen, C₁₋₄ alkyl or CO₂Et or when both X and Y are O, then R₁ to R₇ are 5 not hydrogen.

The invention also provides a process for the preparation of the compound of formula Ia defined above which comprises condensing a compound of formula II:

10



15

II

in which X, Y, R₃ to R₇ are as defined in formula Ia above

with a compound of formula III:

20




III

in which R₁ and R₂ are as defined in formula Ia above.

25

The invention further provides a process for the preparation of the compound of formula Ia defined above which comprises reacting a compound of formula IV:

30



IV

35

in which X, Y, R₁ to R₇ are as defined in formula Ia above with C(NO₃)₄.

The processes are preferably performed in the

- 8 -

presence of a catalyst, such as, an amine or an alkali metal hydroxide, for example, NaOH or KOH.

In a further aspect, the invention provides a pharmaceutical or veterinary composition comprising the
5 compound of formula Ia defined above together with a pharmaceutically or veterinarily acceptable carrier.

Preferably, the pharmaceutical or veterinary composition is a topical, oral or parenteral composition.

The pharmaceutically or veterinarily acceptable
10 carrier is preferably an organic solvent such as acetone, benzene, acetonitrile, DMSO or an alcohol, for example, methanol or ethanol. While the compounds of the present invention show a poor solubility in water, when water is combined with an organic solvent a stable mixture is
15 formed.

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this specification it will be clearly understood that the word "comprising" means
20 "including but not limited to", and that the word "comprises" has a corresponding meaning.

The term "heteroatom" denotes O, N or S.

The term "non-deleterious substituent" is used herein in its broadest sense and refers to a substituent
25 which does not have a deleterious effect on the antimicrobial or radioprotective properties of the compound. Examples include alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, aryloxy, benzyloxy,
30 haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl,
35 acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphenyloxy, heterocyclyl, heterocycloxy, heterocyclamino, haloheterocyclyl, alkylsulphenyl,

- 9 -

arylsulphenyl, carboalkoxy, carboaryloxy mercapto, alkylthio, arylthio, acylthio and phosphorus-containing compounds.

Particularly suitable non-deleterious substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, nitroalkyl, nitroalkenyl and nitroalkynyl.

In a preferred embodiment the non-deleterious substituents are C₁₋₆ alkyl, halo, hydroxy, C₁₋₆ alkoxy and nitro.

The term "optionally substituted" means that a group may or may not be further substituted with, for example, the groups specified above under the definition of non-deleterious substituent.

The term "halogen" refers to fluorine, chlorine, bromine and iodine, preferably chlorine and bromine.

The term "alkoxy" is used herein in its broadest sense and refers to straight chain, branched chain or cyclic oxy-containing radicals each having alkyl portions, preferably C₁₋₆ alkyl, more preferably C₁₋₄ alkyl. Examples of such alkoxy groups are methoxy, ethoxy, propoxy, butoxy and t-butoxy.

The terms "C₁₋₄ alkyl" or "C₁₋₆ alkyl" used either alone or in compound words such as "optionally substituted C₁₋₄ or C₁₋₆ alkyl" refer to straight chain, branched chain or cyclic hydrocarbon groups having from 1 to 6 carbon atoms. Illustrative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

The salts of the compound of formula I or Ia are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts. Examples of

- 10 -

pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, trihalomethanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.

In addition, some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.

By "pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt, hydrate or any other compound which, upon administration to the subject, is capable of providing (directly or indirectly) a compound of formula I or Ia or an antimicrobial or radioprotective active metabolite or residue thereof.

The term "pro-drug" is used herein in its broadest sense to include those compounds which are converted *in vivo* to compounds of formula I or Ia.

The term "tautomer" is used herein in its broadest sense to include compounds of formula I or Ia which are capable of existing in a state of equilibrium between two isomeric forms. Such compounds may differ in the bond connecting two atoms or groups and the position of these atoms or groups in the compound.

The term "isomer" is used herein in its broadest sense and includes structural, geometric and stereo isomers. As the compound of formula I or Ia may have one

- 11 -

or more chiral centres, it is capable of existing in enantiomeric forms.

The term "microbial infection" is used herein in its broadest sense and refers to any infection caused by a 5 microorganism and includes bacterial infections, fungal infections, yeast infections and protozoal infections.

The term "microorganism" includes any microscopic organism or taxonomically related macroscopic organism within the categories algae, bacteria, fungi, yeast and 10 protozoa or the like.

Bacterial infections include, but are not limited to, infections caused by *Bacillus cereus*, *Bacillus anthracis*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium tetani*, *Clostridium perfringens*, *Corynebacteria diphtheriae*, *Enterococcus (Streptococcus D)*, *Listeria monocytogenes*, *Pneumococcal infections (Streptococcus pneumoniae)*, *Staphylococcal infections* and *Streptococcal infections*; Gram Negative bacteria including *Bacteroides*, *Bordetella pertussis*, *Brucella*, *Campylobacter infections*, 20 *enterohaemorrhagic Escherichia coli (EHEC/E. coli 0157 : H7)* enteroinvasive *Escherichia coli (EIEC)*, enterotoxigenic *Escherichia coli (ETEC)*, *Haemophilus influenzae*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Legionella spp.*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, 25 *Neisseria meningitidis*, *Proteus spp.*, *Pseudomonas aeruginosa*, *Salmonella spp.*, *Shigella spp.*, *Vibrio cholera* and *Yersinia*; acid fast bacteria including *Mycobacterium tuberculosis*, *Mycobacterium avium-intracellulare*, *Myobacterium johnei*, *Mycobacterium leprae*, atypical 30 bacteria, *Chlamydia*, *Mycoplasma*, *Rickettsia*, *Spirochetes*, *Treponema pallidum*, *Borrelia recurrentis*, *Borrelia burgdorffii* and *Leptospira icterohemorrhagiae* and other miscellaneous bacteria, including *Actinomyces* and *Nocardia*.

Fungal infections include, but are not limited 35 to, infections caused by *Alternaria alternata*, *Aspergillus flavus*, *Aspergillus fumigatus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus versicolor*, *Blastomyces*

- 12 -

dermatiditidis, Candida albicans, Candida dubliensis, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida glabrata, Coccidioides immitis, Cryptococcus neoformans, Epidermophyton floccosum, Histoplasma capsulatum,

5 *Malassezia furfur, Microsporum canis, Mucor spp., Paracoccidioides brasiliensis, Penicillium marneffei, Pityrosporum ovale, Pneumocystis carinii, Sporothrix schenckii, Trichophyton rubrum, Trichophyton interdigitale, Trichosporon beigelii and Rhodotorula spp..*

10 Yeast infections include, but are not limited to, infections caused by *Brettanomyces clausenii, Brettanomyces custerii, Brettanomyces anomalous, Brettanomyces naardenensis, Candida himilis, Candida intermedia, Candida saki, Candida solani, Candida tropicalis, Candida versatilis, Candida bechii, Candida famata, Candida lipolytica, Candida stellata, Candida vini, Debaromyces hansenii, Dekkera intermedia, Dekkera bruxellensis, Geotrichum sandidum, Hansenula fabiani, Hanseniaspora uvarum, Hansenula anomala, Hanseniaspora guillermondii*

15 *Hanseniaspora vinae, Kluyveromyces lactis, Kloekera apiculata, Kluyveromyces marxianus, Kluyveromyces fragilis, Metschikowia pulcherrima, Pichia guilliermodii, Pichia orientalis, Pichia fermentans, Pichia membranefaciens, Rhodotorula Saccharomyces bayanus, Saccharomyces cerevisiae, Saccharomyces dairiensis Saccharomyces exigus, Saccharomyces uinsporus, Saccharomyces uvarum, Saccharomyces oleaginosus, Saccharomyces boulardii, Saccharomycoides ludwigii, Schizosaccharomyces pombe, Torulaspora delbruekii, Torulopsis stellata,*

20 *Zygoaccharomyces bailli and Zygosaccharomyces rouxii.*

25 Protozoal infections include, but are not limited to, infections caused by *Leishmania, Toxoplasma, Plasmodia, Theileria, Anaplasma, Giardia, Trichomonas, Trypanosoma, Coccidia, and Babesia. Specific examples include*

30 *Trypanosoma cruzi, Eimeria tenella, Plasmodium falciparum, Plasmodium vivax or Plasmodium ovale.*

Preferably, the microbial infection is an

- 13 -

infection caused by either a Gram Positive or a Gram negative bacterium, for example, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumonia*, *Salmonella typhimurium* or *pseudotuberculosis*, *Acinetobacter*,

5 *Pseudomonas aeruginosa*, *Clostridium perfringens*,
Clostridium difficile, *Campylobacter jejuni* or *Bacteroides fragilis*; a fungal or yeast infection, for example, *Trichophyton interdigitale*; *Aspergillus fumigatus* or *Candida albicans*; or a protozoal infection, for example
10 *Plasmodium falciparum* or *Trichomonas vaginalis*.

Examples of microbial infections include bacterial or fungal wound infections, mucosal infections, enteric infections, septic conditions, pneumonia, trachoma, ornithosis, trichomoniasis, fungal infections and
15 salmonellosis, especially in veterinary practice. The compounds of the invention may also be used for the treatment of resistant microbial species or in various fields where antiseptic treatment or disinfection of materials is required, for example, surface disinfection.

20 The term "subject" as used herein refers to any animal having a disease or condition which requires treatment with a pharmaceutically-active agent. The subject may be a mammal, preferably a human, or may be a domestic or companion animal. While it is particularly
25 contemplated that the compounds of the invention are suitable for use in medical treatment of humans, it is also applicable to veterinary treatment, including treatment of companion animals such as dogs and cats, and domestic animals such as horses, ponies, donkeys, mules, llama,
30 alpaca, pigs, cattle and sheep, or zoo animals such as primates, felids, canids, bovids, and ungulates.

Suitable mammals include members of the orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla. Members of the orders
35 Perissodactyla and Artiodactyla are particularly preferred because of their similar biology and economic importance.

For example, Artiodactyla comprises approximately

- 14 -

150 living species distributed through nine families: pigs (Suidae), peccaries (Tayassuidae), hippopotamuses (Hippopotamidae), camels (Camelidae), chevrotains (Tragulidae), giraffes and okapi (Giraffidae), deer 5 (Cervidae), pronghorn (Antilocapridae), and cattle, sheep, goats and antelope (Bovidae). Many of these animals are used as feed animals in various countries. More importantly, many of the economically important animals such as goats, sheep, cattle and pigs have very similar 10 biology and share high degrees of genomic homology.

The order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. Indeed, it is well known that horses and donkeys interbreed.

15 As used herein, the term "effective amount" is meant an amount of a compound of the present invention effective to yield a desired antimicrobial or radioprotective activity.

20 The specific "effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the subject, the type of subject being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compound or 25 its derivatives.

30 The term "radiation damage" is used herein in its broadest sense and refers to damage resulting from exposure to a radiation source, such as, ionising radiation. The term "ionising radiation" as used herein refers to photons having enough energy to ionise a bond, such as, α , β and γ rays from radioactive nuclei and x-rays.

The term "cancer radiotherapy" is used herein in its broadest sense and include radiotherapy involving tumours which may be either benign or malignant.

35 The primary application of the radioprotector of the present invention is in cancer radiotherapy. Many of the normal tissues which are a problem in radiotherapy such

- 15 -

as the skin, oral mucosa, oesophageal mucosa, rectal mucosa, vaginal mucosa and bladder epithelium can be protected by the radioprotectors of the present invention.

Outside the context of cancer radiotherapy, the
5 radioprotectors of the present invention could be used prophylactically in high risk radiation situations.

The compounds of the present invention may additionally be combined with other medicaments to provide an operative combination. It is intended to include any
10 chemically compatible combination of pharmaceutically-active agents, as long as the combination does not eliminate the activity of the compound of formula I or Ia. It will be appreciated that the compound of the invention and the other medicament may be administered separately,
15 sequentially or simultaneously.

Other medicaments which may be used when treating microbial infections include other anti-infective agents such as antibiotics.

When the compounds are used as radioprotectors
20 the other medicaments may include chemotherapeutic agents, for example, radiomimetic agents which are cytotoxic agents that damage DNA in such a way that the lesions produced in DNA are similar to those resulting from ionising radiation. Examples of radiomimetic agents which cause DNA strand
25 breaks include bleomycin, doxorubicin, adriamycin, 5FU, neocarcinostatin, alkylating agents and other agents that produce DNA adducts. It is anticipated that the radioprotectors of the present invention will protect DNA from damage by some of these agents, in the same way as
30 they protect against the effects of ionising radiation. In clinical applications, it is unlikely that the radioprotector would be administered systemically together with the chemotherapeutic agent, since this could compromise the action of this agent on the tumour.
35 However, there are circumstances where topical application to problem tissues could be advantageous. For example, oral mucositis is problem side-effect for cytotoxic agents,

- 16 -

such as, doxorubicin and administration of the present radioprotector as a mouth-wash before administration of the chemotherapeutic agent could ameliorate this side-effect without compromising the action of this agent on a tumour
5 not located in the oral cavity. Similarly, the gastrointestinal tract could be protected by oral administration, the lungs by aerosol inhalation or the bladder by intravesical delivery, for example, via a catheter of the radioprotector. Hence a preferred method
10 in accordance with the present invention utilises the compound of formula I or Ia in conjunction with another medicament, such as, a radiomimetic agent.

The compounds of the invention may be conjugated to agents, for example, via the interactive group, which
15 will specifically deliver them to a desired tumour site. Suitable agents may include antibodies or proteins, growth factors, for example, haemopoietic growth factor which will enable preferential radioprotection of haemopoietic stem cells to occur in the context of total body irradiation and
20 bone marrow transplantation.

There is also an *ex vivo* application of the conjugates of the compounds of the invention in the context of bone marrow transplantation. Bone marrow transplantation generally involves obtaining and storing
25 bone marrow samples from a subject in anticipation of a deterioration of their condition. A rather drastic form of chemotherapy (i.e. a high dose) is then administered. This chemotherapy is such that it would normally be lethal due to the destruction of normal stem cells, but the subject is
30 rescued by the administration of their own haemopoietic stem cells. The problem with this procedure is that the initial sample of stem cells is likely to be contaminated with tumour cells and various procedures are used therefore to purge the bone marrow preparations of the tumour cells.
35 Radioprotectors conjugated to a haemopoietic growth factor could be used in this context by being added to a suspension of bone marrow cells. The suspension could then

- 17 -

be irradiated in the expectation that the normal bone marrow cells, but not the tumour cells, would be preferentially protected from the cell-killing effects of the radiation.

5 As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the compound of formula I or Ia to the subject. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.

10 Each carrier must be pharmaceutically "acceptable" in the sense of being compatible with other ingredients of the composition and non injurious to the subject.

The compound of formula I or Ia may be administered orally, topically, or parenterally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous injections, aerosol for administration to lungs or nasal cavity, intravenous, intramuscular, intrathecal, intracranial, injection or infusion techniques.

The present invention also provides suitable topical, oral and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs. The composition for oral use may contain one or more agents selected from the group of sweetening agents, flavouring agents, colouring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharin. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavouring agents include peppermint oil, oil of

- 18 -

wintergreen, cherry, orange or raspberry flavouring. Suitable preservatives include sodium benzoate, vitamin E, alphatocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include 5 magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate. The tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable 10 for the manufacture of tablets.

These excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; 15 (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained 20 action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Coating may also be performed using techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotic therapeutic 25 tablets for control release.

The compound of formula I or Ia as well as the pharmaceutically-active agent useful in the method of the invention can be administered, for *in vivo* application, parenterally by injection or by gradual perfusion over time 30 independently or together. Administration may be intravenously, intraarterial, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally or infusion by, for example, osmotic pump. For *in vitro* studies the agents may be added or dissolved in an 35 appropriate biologically acceptable solvent or buffer and added to a cell or tissue.

Preparations for parenteral administration

- 19 -

include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic
5 esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated
10 Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, growth
15 factors and inert gases and the like.

Generally, the terms "treating", "treatment" and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure of a disease. "Treating" as used herein covers any treatment of, or prevention of disease in a vertebrate, a mammal, particularly a human,
20 and includes: (a) preventing the disease from occurring in a subject that may be predisposed to the disease, but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or (c) relieving or ameliorating the effects of the disease, i.e., causing regression of the effects of the disease.
25

The invention includes various pharmaceutical compositions useful for ameliorating disease. The pharmaceutical compositions according to one embodiment of the invention are prepared by bringing a compound of formula I or Ia, analogues, derivatives or salts thereof, or combinations of compound of formula I or Ia and one or more pharmaceutically-active agents into a form suitable
30
35

- 20 -

for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein,
5 gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include
10 antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 20th ed.
15 Williams & Williams (2000), the British National Formulary, 43rd edition (British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000), the contents of which are hereby incorporated by reference.
The pH and exact concentration of the various components of
20 the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed., 1985).

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units
25 may be tablets, capsules and suppositories. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses can be used. Under certain circumstances, however, higher or
30 lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

35 The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this

use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration 5 of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of the microbial infections. Various considerations are described, e.g., in Langer, Science, 249: 1527, (1990). Formulations for oral use may be in the form of hard 10 gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as 15 peanut oil, liquid paraffin or olive oil.

Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension. Such excipients may be 20 (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty 25 acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as 30 polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.

The pharmaceutical compositions may be in the 35 form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting

- 22 -

agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as
5 a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this
10 purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compound of formula I or Ia may also be
15 administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

20 The compound of formula I or Ia may also be presented for use in the form of veterinary compositions, which may be prepared, for example, by methods that are conventional in the art. Examples of such veterinary compositions include those adapted for:

25 (a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions); tablets or boluses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue;

30 (b) parenteral administration for example by subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced in the udder via the teat;

35 (c) topical applications, e.g. as a cream, ointment or spray applied to the skin; or

(d) intravaginally, e.g. as a pessary, cream or

foam.

Dosage levels of the compound of formula I or Ia of the present invention may be of the order of up to about 1g per kilogram body weight. The amount of active 5 ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain up to about 1g of an active compound 10 with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.

15 Optionally the compounds of the invention are administered in a divided dose schedule, such that there are at least two administrations in total in the schedule. Administrations are given preferably at least every two hours for up to four hours or longer; for example the 20 compound may be administered every hour or every half hour. In one preferred embodiment, the divided-dose regimen comprises a second administration of the compound of the invention after an interval from the first administration sufficiently long that the level of active compound in the 25 blood has decreased to approximately from 5-30% of the maximum plasma level reached after the first administration, so as to maintain an effective content of active agent in the blood. Optionally one or more subsequent administrations may be given at a corresponding 30 interval from each preceding administration, preferably when the plasma level has decreased to approximately from 10-50% of the immediately-preceding maximum.

It will be understood, however, that the specific dose level for any particular patient will depend upon a 35 variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration,

- 24 -

rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

BRIEF DESCRIPTION OF THE FIGURES

5 Fig. 1 is a graph of Log. No. survivors vs time (hours) for *Candida albicans* in Example 9; and
Fig. 2 is a graph of % parasitised blood cells vs hours of culture in Example 26 in which T = Trophozoites, R = Rings and T/S = Trophozoites or Schizonts.

10

EXAMPLES


The invention will now be described in detail by way of reference only to the following non-limiting examples and drawings.

15


Example 1 General Synthesis Methods

Benzdioxols are described in the literature (Perekalkin, 1982a). The synthesis of benzoimidazole and benzoxazole may also be carried out using standard condensation methods 1 and 2 (Perekalkin, 1966, 1982b) as shown below.

Method 1



Method 2



- 25 -

in which X, Y, ~~Z~~ and R₁ to R₇ are as defined in formula I above.

In Method 2, equimolecular quantities of benzaldehyde and nitroalkane were mixed in an Erlenmayer flask and dissolved in equal volume of alcohol. Fresh distilled ethylenediamine was added to the obtained solution in catalytical quantities (usually 1:10 in relation to aldehyde and nitroalkane) and was left in the dark at room temperature for several days (from 3 up to 10 days). During this time compound crystallised. After the cooling up to about 0°C, the crystals were filtrated and washed with cold alcohol and then dried. When the yield is small, the mother liquids can be joined together and evaporated in rotary evaporator. After cooling the additional quantity of impure product is obtained. The product was purified by dissolving in a minimal quantity of boiling alcohol. It was then treated with activated carbon, filtered hot and while the cooling was in progress, fine yellow needles crystallised. The yield was about 80 - 85%, the compound being chromatographically homogeneous.


The infrared spectra of the compounds obtained are in accordance with those described in the literature (Hamlin and Weston, 1949; Knoevenagel and Walter, 1904; Burton and Duffield, 1949).

The compounds were soluble in organic solvents such as ethanol, acetone, benzene, methanol, acetonitrile, chloroform and DMSO, but showed very poor solubility in water (0.1%). When an alcoholic solution was added to water, a stable colloidal mixture was formed.

Example 2 Method for Preparing Compound (1) (3,4-methylenedioxy-β-methyl-β-nitrostyrene)

Compound (1) was prepared using Method 1 described in Example 1 above. The reaction scheme is shown below.

- 26 -



5

A mixture of 9.8 g of tetranitromethane (1 mole) and 10 cm³ of acetone was cooled by ice and added dropwise to 8.1 g of distilled isosafrole (1 mole) and 4.8 g of pyridine (1.2 mole) dissolved in 20 cm³ of acetone. The
 10 very first drops caused darkening of the reaction mixture and the liquid turned non-transparent and murky red when the entire portion of tetranitromethane was added. The smell of tetranitromethane disappeared quickly and in approximately 2 hours the dark red solution which had
 15 turned transparent was poured into 100 cm³ of water in a stoppered bottle. The mixture was thoroughly shaken, covered with a layer of ether and a mixture of 6.7 cm³ of
 20 33% solution of caustic potassium (1.03 mole) and 50 cm³ of water was added in small portions. The mixture was shaken after each addition and once the entire amount of alkali was added, the shaking was continued until the entire salt of pyridine and nitroform, which is present as a dark red oil, disappeared. The water layer was then separated and again extracted with ether. Combined ether extracts were
 25 first rinsed with water and then with water acidified with sulphuric acid and finally once again with pure water. After distillation of the ether in the vacuum, a sediment of β-nitroisosafrole was to be found in the form of yellow needles, which were re-crystallized from approximately
 30 65 cm³ of alcohol. Compound (1) was obtained with a melting point of 98°C and a yield of 7 g. Once the solvent had evaporated, another 0.5 g of Compound (1) was obtained. The total product amounted to 72.5% of the theoretical yield.

- 27 -


Example 3

Alternative Method for Preparing Compound

(1) (3,4-methylenedioxy-β-methyl-β-nitrostyrene)

5

Compound (1) was prepared using Method 2 described in Example 1 above. The reaction scheme is shown below.



900gm piperonal was dissolved in 1000cc alcohol
 15 with constant shaking and 450ml nitroethane was added slowly followed by 10ml ethyldiamine. After 17hrs stirring, the mixture was placed in the dark at room temperature for 5-7 days. The resulting yellow crystals were filtrated in a Buchner funnel until dried and then washed twice with 150ml alcohol. This yielded 1200gm of Compound (1) with melting point of 95°C. After further crystallization from ethanol, 1000gm of light yellow crystals were obtained with a melting point of 98°C. (approx 80% yield).

25

Molecular formula C₁₀H₉NO₄, molecular weight - 207.05

Physical and Chemical characteristics

30 Form of state yellow crystals
 Solubility profile < soluble in ethanol, acetone, benzene, methanol, acetonitrile, chloroform, DMSO
 - almost insoluble in water
 35 Melting point 94-98°C (when crystallized from 50% ethanol product had 96-98°C)
 pH (in 50% v/v ethanol) approximately neutral

- 28 -

Specific rotation	optically inactive but has 2 stereoisomers
Stability	begins to darken above 200°C
Purity	MS indicates impurities of
5	molecular weight 303.4 & 331.4 to be the major impurities

IR Spectrum

10 1. Aromatic ring - above 3000 wave number & associate aromatics 1470 - 1630 region
2. β -methylstyrene - additional groups over styrene 1442 aliphatic -C- + 900 -1000 peaks
3. Nitrogroup at low wave number e.g. 747, 673 and
15 β -nitrostyrene has 1520.
4. Aromatic Ether Group - 1312 (1258) 1138, 1030
Nevertheless a fingerprint of this compound is provided by the IR spectrum (q.v.). This has
been done on the recrystallised material in order
20 to reduce peaks due to contaminants.

IR Spectrum

Impurities of molecules weight 303.4 & 331.4
25 Confirmation of molecular weight of main species 207.1

NMR Spectrum

30 - Hydrogen NMR (200 MHz) shows:
Aromatic ring with 3 remaining Hs, 3 Hs as part of a CH₃, another attached to the side chain and 2 Hs as part of another ring.
- Carbon NMR (50 MHz) shows:
-CH₃, CH-, -CH₂ (as methylenedioxy)
35 - Values of chemical shifts support the structure given and a likelihood of the E-stereoisomer rather than the Z-stereoisomer favoured by the synthesis used. A

- 29 -


strong -withdrawing group (NO_2) is indicated.

UV/visible Spectrum

5 Recrystallised material has peaks (broad) at 250-270 mm and 360-370 mm with high absorbance below 210mm.

Example 4 Process for Preparing Compound (2)

10 Compound (2) was prepared using Method 2 described in Example 1 above. The reaction scheme is shown below.



3,4-methylenedioxobenzaldehyde was condensed with nitromethane using fresh distilled ethylenediamine $\text{NH}_2\text{-CH}_2\text{-CH}_2\text{-NH}_2$ as a catalyst. The reaction was conducted in alcohol, darkness and at room temperature for 5 days. The resultant crystals were separated by filtration and washed with cold alcohol. After being dried in air, the yield was 80%, m.p. - 158-159°C and after re-crystallization the m.p. was 162-163°C. Compound (2) was non-soluble in water, soluble in acetone, alcohol, acetic acid and in a majority of organic solvents.

Example 5 Antibacterial activity

30 In the experiments described herein, museum strains of pathogens obtained from the museum of the Microbiology chair of the Military Medical Academy (designated by the index "M") and strains selected from pathological material (designated by the index "B"), taken from patients and having gone through no more than three laboratory passages were used. For each type of pathogen the corresponding optimal nutrient media was used. For the

- 30 -

impregnation method, compounds (1) and (2) were added to solid nutrient media at doses from 0.03% to 2.0%. An agar diffusion assay analogous to the standard method of determining sensitivity to antibiotics was used.

5 The agar diffusion assay was performed as follows.

Meat peptone agar was prepared and impregnated with the test compounds at concentrations from 0.01 to 2.0%. The medium was poured into Petri dishes and allowed 10 to set. Agar plugs of 10 mm diameter were cut out and placed on the surface of Petri dishes containing the same medium immediately after they were inoculated with the microorganisms to be investigated (at least 6 plugs per culture). After one day of incubation at 37°C, the diameter 15 of the zone of retardation of growth of the culture around the plugs was measured. The results were evaluated in accordance with official standards of testing sensitivity to antibiotics; a diameter ≤ 20 mm corresponded to a stable culture, 21-28 mm to moderate stability and ≥ 29 mm to 20 sensitivity.

In parallel to this, the sensitivity of pathogens to 15 antibiotics were tested according to the official protocol of the Russian Supervisory Authority for the Introduction of New Medicinal Substances and Medical 25 Technology (disc method).

Several pathogen types and strains were used to show the limits of sensitivity of the strains and types to the test substances, in order to evaluate their probable overall breadth of performance.

30 Table 1 below shows the results of experiments with Compound (1) at a concentration of 1.0%, at which it suppressed the propagation of 5×10^5 - 5×10^7 organisms/mL, and comparative results of sensitivity experiments using the following 15 antibiotics:

35

- 1 - penicillin,
- 2 - ampicillin,

- 31 -

- 3 - gentamycin,
- 4 - carbenicillin,
- 5 - kanamycin,
- 6 - lincomycin,
- 5 7 - levomicethin,
- 8 - oxacillin,
- 9 - polymixin,
- 10 - rifampicin,
- 11 - ristomycin,
- 10 12 - streptomycin,
- 13 - tetracycline,
- 14 - erythromycin,
- 15 - cephalosporin.

Table 1

- 33 -

- 34 -

Remarks:

- + sensitive strains
- ± moderately sensitive strains
- stable strains

5

Table 2 below shows the results of experiments on sensitivity of some microorganisms to Compound (1) using the agar diffusion method described above.

- 35 -

Table 2

Microorganism	Diameter of zone of Growth inhibition (mm)		
	Concentration in disc of Compound (1) (%)		
	2.0	1.0	0.1
γ -haemolytic streptococcus B-672	35#	34#	32#
β -haemolytic streptococcus B-624	31#	32#	31#
Staphylococci aureus B-685	39#	37#	35#
Staphylococci epidermidis B-513	38#	34#	32#
Shigella flexneri M- 2A6907	36#	33#	31#
Shigella sonnei B- 720	39#	35#	30#
Salmonella typhimurium M-727	32#	30#	24#
Salmonella paratyphi M-16469	36#	30#	28#
Acinetobacter B-681	38#	35#	32#
Alkaligenes sp. B-689	40#	38#	36#
Enterobacter agglomerans B-679	33#	30#	25#
Corynebacterium B- 670	40#	35#	31#
Bacillus sp. B-575	38#	34#	29

Remarks:

sensitive

5 + moderately sensitive

- stable

Table 3 shows the results of experiments of sensitivity of pathogenic fungi to compound (1).

- 36 -

Table 3

Fungi	Dosage of Inoculation	Result	Number of microbes in the presence of Compound (1) at concentration (%)		
			2.0	0.5	0.1
<i>Candida albicans</i> B-45	5×10^4	Growth	0	0	0
		Retardation	5×10^4	5×10^6	5×10^6
<i>Candida albicans</i> M-3	5×10^4	Growth	0	0	0
		Retardation	5×10^6	5×10^6	5×10^6
<i>Trichophyton</i>	10^2	Growth	0	0	0
		Retardation	10^7	10^7	10^7
<i>Geotrichum</i> M-158	10^5	Growth	0	0	0
		Retardation	10^5	10^5	10^4
<i>Torula histolytica</i> (<i>Cryptococcus</i>)	10^5	Growth	0	0	0
		Retardation	10^5	10^5	10^5

5 Example 6 Antimicrobial tests

The antimicrobial activity of Compound (1) was tested, using the agar diffusion method.

Due to the very low solubility of the compounds,
10 the studies could not be carried out in the liquid phase.
For this reason an initial mother impregnate, containing
0.5% of test compound, was prepared on meat peptone agar.
From this mother impregnate, regenerated to the liquid
state in a water bath, serial double dilutions were
15 prepared by addition of the agar base. The dilutions thus
obtained, containing the compounds in concentrations of
0.5%, 0.25%, 0.12%, 0.06%, 0.03%, 0.015% were poured into
Petri dishes, on which 6 bacterial and 2 fungal test
cultures were inoculated.

20 The following test cultures were used:

- 1) *Staphylococcus aureus* strain 674, isolated from a

- 37 -

patient, sensitive to gentamycin, oxacillin,
tetracycline, erythromycin and cephalothin, slightly
sensitive to streptomycin.

2) *Enterococcus faecalis* museum strain, sensitive to
5 ampicillin, rifampicin, and streptomycin.

3) *Klebsiella pneumoniae* strain 312, isolated from a
patient, sensitive to gentamycin and polymyxin.

4) *Salmonella typhimurium* museum strain 727, sensitive to
ampicillin, gentamycin, carbenicillin, canamicillin,
10 polymyxin, and cephalothin.

5) *Acinetobacter* strain 681, isolated from a patient,
slightly sensitive to polymyxin.

6) *Pseudomonas aeruginosa* strain 328, isolated from a
patient, slightly sensitive to polymyxin.

15 7) *Trichophyton interdigitale*.

8) *Candida albicans*.

Each of the 8 test cultures was sown on sterile
meat peptone agar in a Petri dish, and then a standard plug
20 of agar, impregnated with one of the 9 compounds at a
concentration of 0.5%, was placed on the agar surface. The
retardation zone was measured around the plug after 24 h
and 48 h growth at 37°C. For the fungal cultures the
results were assessed after 7-10 days of incubation at
25 30°C.

The results of the action of the compound on the
impregnated agar are summarised in Table 4.

- 38 -

Table 4

	Minimal & Compound (1) giving complete inhibition of test culture	% inhibition by antibiotic
<i>S. aureus</i>	0.015	5.5
<i>Enterococcus faecalis</i>	0.015	3
<i>Klebsiella pneumoniae</i>	0.12	2
<i>Salmonella typhimurium</i>	0.5	5
<i>Acinetobacter</i>	0.12	1
<i>Pseudomonas</i>	-	1.5
<i>Trichophyton</i>	0.25	-
<i>Candida</i>	0.5	-
<i>Activity Index</i>	0.4	-

Table 5 below shows the results of the agar diffusion experiments:

Table 5
Results of growth retardation by the compounds in the diffusions in the agar experiment

10

Test culture	Size of zone of retardation of the growth by Compound (1)
<i>Staphylococcus aureus</i>	6.5
<i>Enterococcus faecalis</i>	6
<i>Klebsiella pneumonia</i>	5
<i>Salmonella typhimurium</i>	7
<i>Acinetobacter</i>	6.5
<i>Pseudomonas</i>	0
Average zone of retardation	5.17

In equal concentration Compound (1) inhibits the growth of ampicillin-resistant *Staphylococcus* and the growth of *Enterococcus* which is sensitive to this antibiotic. Similar differences can be observed with other pathogens and other preparations.

- 39 -

Anti TB Effects of Compound (1)

Anti TB effect was checked by standard method of serial double dilutive in synthetic liquid medium (SOTON) 5 with 10% normal equine serum. The solution was prepared in Tween 80.

Test culture was Mycobact tub. H.37RV sensitive to anti TB medication.

10 Mycobacterial suspension (density 5×10^7 cells/ml) was spread onto a special liquid medium (Vischnevsky, B.I.)

Results were calculated for 10 - 14 days incubation at 37°C. MIC (totally inhibiting *M. tuberculosis*)

15 The results are shown in Table 6 below.

Table 6

	Minimal Inhibitory Concentration ($\mu\text{g}/\text{ml}$)
Compound (1)	6.25
Isoniazid	0.02-0.1
Rifampicin	0.01-0.02
Ethambutol	1.0-2.5
Streptomycin	0.5

20 Only Compound (1) had MIC close to Ethambutol / Isoniazid MIC.

Example 7 Anti-protozoal activity

25 The effect of the Compounds (1) and (2) on trichomonas was also investigated. *Trichomonas vaginalis* isolated from patients was used. The trichomonads were cultured at pH 5.8-6.5 and 37°C in medium 199 containing 5.0% native foetal calf serum, carbohydrates, and 30 antibiotics to suppress the accompanying flora. Vaseline

- 40 -

was applied to the surface of the medium in the culture tube. The experimental specimens contained the test compounds at a concentration of 0.3%.

7 specimens were investigated, containing motile forms of the parasite in a quantity of 5-8 cells in 1.0 cm³. In the control, parasites were cultured successfully over 3-4 passages (each passage 5-6 days). In contrast, culture of motile forms in medium containing the test compounds was unsuccessful in every case. After only one 10 passage in the presence of the test compounds, motile forms did not propagate.

Example 8 Anti-bacterial activity in vivo

15 The therapeutic and prophylactic effect of the substances was determined in experiments *in vivo* on mice, infected intraperitoneally or intranasally with *Corynebacterium paratuberculosis*.

20 Compounds (1) and (2) were administered intraperitoneally, intramuscularly and orally at a dose of < 20% LD₅₀/0.2 at different periods from the day of infection, ie 2 and 1 days before the infection (schedules 2, 1), on the day of infection (schedule 0) and 1, 2, 3 etc. days after the infection (schedules +1, +2, +3, etc).

25 The daily mortality rate was measured, their cumulative variations were calculated and based on this the results of the performance of the preparation was determined by the formula

30 $AI = [(B-A):B] \times 100$

where AI = activity index of the preparation (%),
A = cumulative mortality in the experimental group,
B = cumulative mortality in the control group.

35 The results are shown in Table 7 below and indicate that Compounds (1) and (2) tested showed

- 41 -

therapeutic and prophylactic activity in mice infected with *Corynebacterium paratuberculosis*.

For intramuscular administration, the clinical prophylactic performance in the form of reduced mortality 5 of animals was 52.53%. The clinical performance for salmonellosis varied within the limits of 50.0-20.0%. For pseudotuberculosis the prophylactic performance was 50.0%.

- 42 -

Table 7
Order of activity of compounds as assessed by AI

Compound	Pathogen and method of infection	Schedule of introduction of the preparation	Incubation period days (test/ control)		Activity index %	
			test	contr.	Cumulative mortality (test/ control)	
					test	contr.
1	Salmonella intraperitoneally	-1, 0, +1, +2, +3	0	0	47	99 +52, 53
		200 mg/kg intramuscularly				
2	Salmonella intranasally	+2, +3	1	0	15	30 +50, 00
		200 mg/kg intramuscularly				

- 43 -

Example 9 Radiation protective activity

The radiation protective performance of the Compounds (1) and (2) investigated was tested on male white
5 mice weighing 18-20 g.

Dosages: 2, 4, 6, 8, 10, 15, 20 Gr (1 hR = 100 Röntgen).

Period of observation = 25 days.

10 Method of reporting: dynamic mortality, calculation of cumulative mortality and factual changes of dosage (FCD).

Schedule of introduction: 50 mg/kg at 0.2 mL in mice.

15 Group 1 - control,
Group 2 - 2 and 1 days up to irradiation.

Table 8 shows the results of the experiments on radiation
20 performance of the compounds investigated.

Table 8

Dosage R (hR*)	Cumulative mortality in groups %	
	control	prophylactic
2	2.9	0
4	3.6	0
6	13.1	3.8
8	21.1	9.5
10	43.8	13.3
15	66.7	45.5
20	94.1	83.3
FCD		1.39 + 1.48
LD ₅₀	10.73 hR	15.88 hR

Remarks:

25 *1hR = 100 Rontgen

The results show that for all irradiation dosages

- 44 -

prophylactic administration of the test compounds considerably decreases the mortality of irradiated animals in comparison with the control group. FCD (LD₅₀ contr.) = 1.39-1.43, which shows a high radiation protective effect 5 of the compounds indicated, the performances of which do not yield to the reported media.

Example 10 Treatment of infected wounds

10 Human volunteers suffering from skin wounds infected by *Streptococcus* and *Staphylococcus* were treated with 0.1% Compounds (1) and (2) in an ointment base of vaseline, sheep fat and sulfoxide. Application of 0.1 % ointment for 3 days cleared the wound completely of pus, 15 with subsequent healing of the wound.

In 3 cases extensive damage to the skin caused by fungal infection was treated; the type of the fungus was not identified. The damaged area was smeared twice per day with 0.1 % ointment. The skin was cleared of fungal growth 20 within a week.

Example 11 Pharmacokinetics

While the pharmacokinetics of the compounds of the 25 invention have not been investigated in detail, in experiments carried out in mice to which Compounds (1) and (2) were administered intraperitonally and intragastrically, it has been established that the compound will remain in a biologically active concentration in the 30 blood for longer than 24 h.

Example 12 Toxicology

The average lethal dose for mice when 35 administered intragastrically was 1500 mg/kg body weight; when administered intraperitonally the average lethal dose was 575 mg/kg body weight. Thus the compounds of the

- 45 -

invention have low toxicity.

Example 13 Antimicrobial Activity and Solubility of Compound (1)

5

Compound (1) is relatively insoluble in water but is soluble in 10% DMSO at 1 mg/mL (0.1%), 10% ethanol at 2 mg/ml and 10% acetone at 2 mg/mL.

10 The highest concentration testable is either 512 µg/mL at 5% solvent or 256 µg/mL at 2.5% solvent. It does not require specific chemical neutralization, dilution being sufficient to neutralize residual activity in microbicidal testing.

15 DMSO was selected as the solvent for testing because it has the lowest toxicity against test strains.

Compound (1) was at least 8 times more active against *E. coli* when formulated in ethanol, giving an MIC of 128 µg/mL (0.06% ETOH) compared to >512µg/mL (2.5% DMSO). Ethanol is toxic to *E. coli* at concentrations > 2.5%.

Example 14 Antibacterial activity of Compound (1)

25 NCCLS-USA Standard Method - Broth microdilution (or macrodilution) (Mueller-Hinton).

Inoculum 1-4 x 10⁴ cfu (or -4 x 10⁵ cfu).

Ciprofloxacin test control. Chlorhexidine values added for disinfectant and antiseptic activity comparison.

30 Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) as 3 log reduction (99.9% kill) at 35°C, 24 hours, aerobically (unless otherwise indicated). 48 h titres were not significantly different.

Results are shown in Table 9.

35

Summary of results

Compound (1) is a relatively broad spectrum

- 46 -

antibacterial agent with bactericidal activity within an acceptable concentration range *in vitro* for a representative selection of Gram positive and Gram negative bacteria. Compound (1) is broadly effective against 5 aerobic Gram positive and Gram negative cocci and aerobic Gram positive rods of clinical significance.

Infections with resistant Gram positive cocci

Clinical isolates (multiple antibiotic 10 resistance) of *S. aureus* and *E. faecalis* were as susceptible as the standard strains. Although not active at the low concentrations of current treatment drugs, there may be a potential use for Compound (1) as a treatment for multiply resistant staphylococci and enterococci not responding to the current drugs of choice. 15

Anaerobic infections

Compound (1) is active against clinically significant anaerobes, *Clostridium perfringens*, *Clostridium difficile* and *Bacteroides fragilis*. *C. difficile* causes enterocolitis in hospitalized patients and is currently treated with vancomycin as the drug of choice. Induction of resistance is a potential problem with vancomycin. There could be a market for an oral drug for *C. difficile* 25 enterocolitis as an alternative to vancomycin.

Anaerobic infections are generally mixed infections of one or more anaerobes with facultative bacteria, usually enteric Gram negative rods. The most common anaerobic pathogens are *Clostridium difficile* and 30 *Bacteroides fragilis*. Current treatment with metronidazole in combination with other antibacterial drugs is generally efficacious. Given Compound (1)'s broad spectrum against both aerobic and anaerobic bacteria this could possibly treat these infections.

35

Enteric infections

Compound (1) is very active against *Campylobacter*

- 47 -

jejuni. *Campylobacter* is currently the greatest cause of enteric infections worldwide and is often treated because of its severity in some patients and the tendency for infection to predispose to development of Guillain-Barre 5 syndrome, a serious CNS disease.

The relative resistance of enteric Gram negative bacteria could be a function of solubility and ability of Compound (1) to penetrate cells. The successful treatment of recalcitrant enteric infections and the successful 10 treatment of *Salmonella* infection in animals has been shown.

Vulvo-vaginitis

Compound (1) is active against *Neisseria gonorrhoeae*. Vulvo-vaginitis is caused by *Candida albicans*, *N. gonorrhoeae*, *Chlamydia trachomatis* and *Trichomonas vaginalis* (singly, not as co-infections). Compound (1) is active against two of these agents.

Formulating Compound (1) for greater solubility 20 (and therefore probably greater absorption) could improve both its activity and its distribution *in vivo*.

- 48 -

Table 9

MIC/MBC ($\mu\text{g/mL}$) for Compound (1), ciprofloxacin and chlorhexidine against a range of bacteria of clinical significance

5

Bacterial strain	Compound (1)		Ciprofloxacin		Chlorhexidine	
Gram positive	MIC	MMC	MIC	MMC	MIC	MMC
<i>Staphylococcus aureus</i> ATCC 29213	16	16	0.25	0.25	2	8
<i>S. aureus</i> - clinical isolate 1	16	16				
<i>S. aureus</i> - clinical isolate 2	16	16				
<i>Enterococcus faecalis</i> ATCC 29212	32	32	0.5	0.5		
<i>E. faecalis</i> - clinical isolate 1	32	32	1	1		
<i>E. faecalis</i> - clinical isolate 2	32	32				
<i>Streptococcus pyogenes</i>	16, 8	16, 8				
<i>Streptococcus pneumoniae</i> ATCC49619	16	32				
<i>Bacillus subtilis</i> RMIT	16	16				
<i>Corynebacterium xerosis</i> RMIT	32, 16	32, 16				
<i>Clostridium perfringens</i> (48 h)	16	32				
<i>Clostridium difficile</i>	4	16				
<hr/>						
Gram negative						
<i>Moraxella catarrhalis</i> RMIT	32	32				
<i>Neisseria gonorrhoeae</i> WHO Strain VII	2	2				
<i>Haemophilus influenzae</i>	0.125	0.125	0.006	0.006		
<i>Bacteroides fragilis</i> (48 h)	16	32				
<i>Campylobacter spp.</i> (48 h)	128	128				
<i>Campylobacter jejuni</i> RMIT FF3 (48 h)	2	2				
<i>Acinetobacter calcoaceticus</i> RMIT	128	256				
<i>Proteus vulgaris</i> RMIT	128	256			6	128
<i>Proteus mirabilis</i>	256	>512				
<i>Klebsiella oxytoca</i>	128	256				
<i>Klebsiella pneumoniae</i>	512	>512				
<i>Salmonella Typhimurium</i>	256	>512				
<i>Escherichia coli</i> ATCC 25922	>512	>512	0.02	0.02	2	4
<i>Pseudomonas aeruginosa</i> ATCC 27853	>512	>512	0.25	0.25	32	64
<i>Serratia marcescens</i> RMIT	>512	>512			16	32
<i>Enterobacter aerogenes</i>	512	512				

- 49 -

Example 15 Antifungal activity of Compound (1)

NCCLS-USA Broth macrodilution method (RPMI medium).

5 Inoculum ~5 x 10⁴ hyphal fragments/mL (haemocytometer). Miconazole control.

Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC 2 log reduction - 99% kill) at 30°C, aerobically, 2, 7 and 10 days for yeasts and
10 4, 7 or 14 days for filamentous fungi.

Results are shown in Table 10.

Summary of results

Compound (1) is fungicidal at relatively low
15 concentrations against a broad range of clinically significant yeasts and filamentous fungi (Table 10).

Dermatophyte infections

Compound (1) shows good activity against 3 major causes of skin, hair and nail infections in humans and animals. Superficial fungal infections are the most common fungal infections worldwide. Treatment is prolonged, over months (and years for nail infections). Superficial treatments with antifungal lotions and creams is only
25 partially effective. Current treatments, although generally low cost, have poor efficacy and frequent relapse rates. Oral systemic agents (terbinafine and itraconazole) are preferred for superficial infections in compromised patients and nail infections.

30

Systemic infections

Serious fungal infections in compromised patients have increased worldwide in prevalence and severity. Fungal infections are generally long term with a high
35 therapeutic failure rate, frequent relapse and development of resistance by fungi. Candidiasis (*Candida albicans*) and aspergillosis (*Aspergillus fumigatus*) are the major fungal

- 50 -

infections. Severe, invasive infections have a high mortality rate. Very few effective drugs are available (*cf* antibacterial drugs). Long term therapy makes safety and failure to induce resistance important considerations.

5 Amphotericin B is the main drug of choice for many serious mycoses. It is fungicidal, with poor solubility and low bioavailability and is limited by toxicity and delivery problems and high therapy failure. The azoles and triazoles are fungistatic drugs (eg fluconazole and
10 itraconazole) which have low toxicity, good pharmacokinetic characteristics but are often ineffective due to development of resistance on long term therapy.

Compound (1) has a broad spectrum, is fungicidal and has failed to induce resistance in *C. albicans* and *A.
15 fumigatus* (see below).

- 51 -

Table 10
**MIC/MFC ($\mu\text{g/mL}$) for Compound (1) and miconazole against
 clinically significant fungi**

Fungi	Compound (1)		Miconazole	
	MIC	MMC	MIC	MMC
Dermatophytes (7 day)				
<i>Trichophyton rubrum</i>	1	256	1	64
<i>Epidermophyton floccosum</i>	0.5	16	0.25	0.25
<i>Microsporum gypseum</i>	1	8	4	64
Yeasts (4 day)				
<i>Candida albicans</i>	8	8	4	8
<i>Rhodotorula rubra</i>	8	8	8	32
Filamentous fungi (7 day)				
<i>Fusarium graminearum</i>	4	8	32	32
<i>Rhizopus stolonifer</i>	4	16		
<i>Aspergillus fumigatus</i>	8	32		
<i>Penicillium chrysogenum</i>	1	2		
	5			

Example 16 Sporicidal activity of Compound (1)

Bacillus subtilis endospores

10 *Aspergillus fumigatus* asexual exospores

Compound (1) in water + Tween 20 was tested for
 sporicidal activity up to 24 hours.

15 Compound (1) 512 $\mu\text{g/mL}$ did not kill *B. subtilis*
 endospores in 24 hours.

Compound (1) 512 $\mu\text{g/mL}$ killed *A. fumigatus*
 exospores at 24 hours but not 6 hours.

Inhalation of *Aspergillus* spores is the major mechanism of transmission. Activity against spores could be significant in prophylaxis of compromised individuals.

5 Since the spore must germinate to infect, however, ultimately it is activity against vegetative forms of fungi that determine efficacy.

Example 17 Development of resistance of Compound (1)

10

Bacterial and fungal strains were exposed to Compound (1) in sub-inhibitory concentrations continuously for 12 weeks and monitored for a rise in MIC indicating development of resistance mechanisms. A heavy and variable inoculum is used for weekly subculture so inhibitory concentrations each week vary. The standardized MIC is measured at the beginning and end of exposure. A greater than 4-fold variation of standardized MIC is indicative of increased resistance, or a rising trend in weekly MIC. The genera selected are known to develop resistance readily to many antibiotics and to be a major clinical problem.

Bacterial species and *C. albicans*, known to develop resistance to many current drugs, did not develop resistance to Compound (1) after 12 weeks continuous exposure (Table 11). Strains were scanned for abnormal microscopic and macroscopic changes. *Proteus vulgaris* lost the ability to swarm, indicating an effect on flagella. Other strains appeared normal. Tests are not yet complete for *R. rubra* and 3 moulds. Failure to induce the development of resistance in these strains is a significant attribute of Compound (1).

- 53 -

Table 11
**Increase in MIC ($\mu\text{g/mL}$) of bacterial and fungal strains
 after 12 weeks continuous exposure to sub-inhibitory
 concentrations of Compound (1) in MHB**

5

Test strains	Standard MIC $\mu\text{g/mL}$		7 day MIC $\mu\text{g/mL}$ no rising trend
	Initial	Final	Range to Week 12
<i>Staphylococcus aureus</i> (MRSA clin isolate)	16	16	32-128
<i>Enterococcus faecalis</i> (MR clin isolate)	32	32	64-128
<i>Klebsiella oxytoca</i>	128	256	256-512
<i>Proteus vulgaris</i>	128	128	64-256
<i>Candida albicans</i>	4	4	16-64
<i>Rhodotorula rubra</i>	8		8-32 to Wk 5
<i>Aspergillus fumigatus</i>	8		8-32 to Wk 5
<i>Rhizopus stolonifer</i>	4		4-32 to Wk 5
<i>Fusarium graminearum</i>	4		4-16 to Wk 5

Example 18 Antibacterial activity of Compound (1) in
 the presence of blood

10 The activity of Compound (1) and ciprofloxacin was determined in the presence of plasma and whole blood (horse), by macrodilution method in Mueller Hinton broth to 48 h.

15 Compound (1) appeared to be relatively unaffected by the presence of 10% plasma and to be more active in the presence of 5% whole blood. The slightly improved inhibitory activity of drugs in the presence of blood sometimes occurs with antibacterial agents and is probably due to natural antibacterial factors present in blood.

20 Further increasing the concentration of plasma and blood reduced the bactericidal activity of Compound (1) against *S. aureus* as shown in Table 13. Ciprofloxacin showed respectively a 4-fold and 2-fold decrease in activity

- 54 -

against *S aureus* in the presence of 10% plasma and whole blood.

Table 12

5 Activity of Compound (1) in the presence of human whole blood and plasma

	$\mu\text{g/mL}$				
	-	10% plasma		5% blood	
	MIC	MIC	MMC	MIC	MMC
<i>S. aureus</i>	16	16	256	16	256
<i>B. subtilis</i>	16	8	8	8	16
<i>A. calcoaceticus</i>	128	128	128	64	256
<i>M. catarrhalis</i>	32	8	8	4	8

Example 19 Compound (1) binding to plasma proteins

10

The MIC of Compound (1) was determined in increasing concentrations of plasma. Compound (1) has been shown to bind to human serum albumin and to agarose. Serum binding is significant in drug distribution and bioavailability.

15

The MIC of Compound (1) is significantly increased with increasing plasma concentrations. Bactericidal activity is much more affected than inhibitory activity.

20

Bioavailability of Compound (1) is significantly decreased in the presence of plasma proteins (Table 13). Compound (1) is reversibly bound to proteins.

- 55 -

Table 13
MIC/MMC ($\mu\text{g/mL}$) for Compound (1) in MHB in the presence of increasing concentrations of plasma

% plasma in MHB	S. aureus	Streptococcus pyogenes
	MIC	MIC
0	4	4
1	4	4
2.5	8	8
5	8	8
10	16	16
20	32	32
50	128	64
100	128	256

5

Example 20 Rate of kill

Test strains were inoculated into Compound (1) solutions in water and sampled immediately and at 1, 2, 4, 10 6 and 9 hours. Survivors were estimated by viable counts on MHA (35°C, 48 h).

Measure of kill: reduction in viable count (log) expressed as log reduction factors.

(e.g., a 1 log reduction = 90% kill, 2 log = 99% kill, 3 log = 99.99% kill etc.)

Compound (1) showed rapid kill only against *Candida albicans*, with greater than a 99.999% reduction within 2 hours at 512 $\mu\text{g/mL}$ and within 4 hours at 256 $\mu\text{g/mL}$ as shown in Fig. 1.

Rate of kill was much slower against bacteria. The kill rate at 512 $\mu\text{g/mL}$ was 99.99% within 2 hours for *B. subtilis* and 99.99% within 9 hours for *S. aureus*.

Ciprofloxacin was not tested.

- 56 -

Table 14
Log reduction factors for Compound (1) over 6 or 9 hours

	Log reduction in viable count at time (h)		
	Compound (1) µg/mL		
	512	256	128
<i>Staphylococcus aureus</i>	4 in 9 h	0.5 in 6 h	
<i>Enterococcus faecalis</i>	0.6 at 9 h		
<i>Bacillus subtilis</i>	4 in 2 h	3.8 in 2 h	
<i>Klebsiella oxytoca</i>	0	0	
<i>Proteus vulgaris</i>	1 in 6 h	0.5 in 6 h	
<i>Acinetobacter calcoaceticus</i>	1 in 6h	1 in 6 h	
<i>Candida albicans</i>	5.5 at 2h	6 in 4h	2 in 6h

5 Example 21 Dosing range test of Compound (1) in rat

The aim of this example was to establish absorption and blood levels of Compound (1) in the rat after a single dose oral administration.

10

Test protocol

Sprague-Dawley rats (6 w/o, delivered 30 Jan, 2001) were acclimatised for 6 days in the Animal Facility under standardized environmental conditions ($22^{\circ}\text{C} \pm 3^{\circ}\text{C}$, rel hum 30-70%, artificial light, 12 h light/12 h dark). Rats were fed a conventional laboratory diet with food and water ad lib and caged 5 rats per cage.

20

Test substance

Compound (1) was prepared as an aqueous suspension in sterile LPW. At higher concentrations the suspension was sonicated to reduce particle size sufficiently to pass through the gavage needle.

25

Compound (1) was tested at 1250, 1000, 500 and

100 mg/kg.

- 57 -

Test method

Rats were randomly assigned to treatment groups, identified by numbering on tails. Doses were tested sequentially from the lowest dose.

5

Group	A	100 mg/kg	5/2/01
	B	500	8/2/01 (not fasted)
	C	500	12/2/01 (fasted)
	D	1000	14/2/01
10	E	1250	21/2/01

Compound (1) suspensions and the water control were administered at approx 100 mL/kgbw, in a single. One control and five treatment rats were weighed immediately 15 before each dose administration, the dose volume calculated and the dose delivered by gavage (22 gauge stainless steel, smooth-balled end attached to a syringe).

Approximately 100-200 µL of blood (microfuge tube) was removed from the tail at 4 and 8 hours. Tails 20 were prewarmed using a heat lamp and snipped at the tip with a large scalpel. Blood was massaged into a microfuge tube. Twenty four hour blood samples were not attempted because of the difficulty of snipping scarred tails and the distress caused to rats.

25 Blood was allowed to clot, centrifuged in a microfuge for 3 minutes (speed 14) and the serum separated and stored at -20°C.

Animals were observed twice daily for 7 days and all observations recorded individually for each animal. 30 Animals were not weighed after the initial weighing. Sacrifice and necropsy was performed at 7 days.

Animals were euthanized by carbon dioxide.

Gross pathology was recorded and samples of heart, lung, liver, kidney, stomach, spleen, duodenum and 35 colon removed (10% formalin) for histology.

- 58 -

Example 22 Blood levels of Compound (1)

Bioassays

5 Bioassay for Compound (1) levels in blood was not possible because of the interference due to strong binding of Compound (1) to blood proteins and to agar.

Agar diffusion

10 An agar diffusion assay for Compound (1) was not possible because Compound (1) bound so strongly to agar that no zones of inhibition were produced at any concentration from 1 to 512 µg/mL with susceptible strains of *S. aureus* or *Streptococcus pyogenes*. Both well diffusion and disk diffusion assays were attempted.

15

Broth dilution

20 Dilution of serum in MHB and testing with a low inoculum of *S. pyogenes* (inhibited at 1 µg/mL of Compound (1) in MHB) was not possible because strong binding to plasma at high concentrations caused a significant prozone.

Assay by UV spectroscopy

25 There was insufficient serum for assay of individual rat samples. Samples for treatment groups and for controls were thus pooled and a mean level of Compound (1) for each treatment group determined.

Test method

30 Compound (1) was extracted (x2) from serum by toluene and absorbance measured at 370 nm (Hitachi U2000). A spiked control using 100 µg/mL Compound (1) in 50% methanol/water (V/V) and untreated controls were also assayed.

35

Blood levels

Absorption of Compound (1) from the

- 59 -

gastrointestinal tract is very low, approximately 2% of the oral dose reaching the blood. Blood levels increased with dose level. Eight-hour levels were generally higher than 4-hour levels. The small difference between 4 and 8 hour
5 levels suggests a slow absorption.

Table 15

Compound (1) dose (mg/kg)	Sample time (hours)	Blood level of Compound (1) µg/mL Mean
500 fed	4	8
	8	17
500 fasted	4	12
	8	14
1000 fasted..	4	26
	8	21
1250	4 + 8 h	27

10 Example 23 Antimicrobial activity spectrum
of Compound (1)

Antifungal activity

15 Filamentous fungi

NCCLS-USA Broth Macrodilution method (RPMI medium) - draft. Inoculum 1-4 x 10⁵ cfu. Miconazole control. This test was used for initial activity spectrum evaluations.

20 The MIC and MFC of filamentous fungi tested previously with the NCCLS-USA Broth Macrodilution Method were repeated using the new proposed standard microdilution method for testing fungi M38-P NCCLS-USA.

25 Results are of 2 or 3 replicates on different days.

Results were not significantly different from

- 60 -

results obtained with the older method for all fungi previously tested. Amphotericin B was substituted for Miconazole as control for some tests.

5 Yeasts

NCCLS - M27-A Method for broth macro dilution antifungal susceptibility testing of yeasts; approved standard.

10 M38-P microdilution method for filamentous fungi also used.

15 Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC - 2 log reduction - 99% kill) at 35°C, 48 hours. Results of 2 or 3 replicates on different days for each method. Results were not significantly different for the two methods. M38P only reported for yeasts and filamentous fungi.

- 61 -

Table 16

**MIC/MFC ($\mu\text{g/mL}$) for Compound (1) and Amphotericin B against
clinically significant fungi - M38 - P method**

	Compound (1)		Amphotericin B		Miconazole	
	MIC	MMC	MIC	MMC	MIC	MMC
Yeasts (24 h, 35°C)						
<i>Candida albicans</i>	8	8	0.25 ₁	0.25		
<i>C. guillermondii</i> RMIT 176	2	2	0.03	0.06	1	1
<i>C. krusei</i> RMIT 177	4	4	0.5 ₂	0.5	2	2
<i>C. parapsilosis</i> RMIT 178	2	2	0.25 ₃	0.25	0.5	0.5
<i>C. tropicalis</i> RMIT 181	4	4	0.25	0.5	1	2
<i>C. glabrate</i> RMIT 157	2	2	0.5	1	0.25	0.5
<i>Cryptococcus neoformans</i>	1		0.5		4	
Filamentous fungi (48h, 35°C)						
<i>Aspergillus fumigatus</i>	8	32	1	8		
<i>A. niger</i>	8	16	2	2		
<i>A. flavus</i>	16	32	8	8		
<i>Fusarium graminearum</i>	4	8	4	8		
<i>F. chlamydosporum</i>	8	8	2	2		
<i>Rhizopus stolonifer</i>	4	16	>16			
<i>R. oryzae</i>	64	64	4	4		
<i>Rhizomucor pusillus</i>	4	8	1	1		
<i>Paecilomyces variotii</i>	1	2	1	1		
Dematiaceous fungi						
<i>Fonsecaea pedrosoi</i>	2	2	8	16		
<i>Phialophora verrucosa</i>	16	32	2	4		
<i>Pseudoallescheria boydii</i>	2	4	4	16		
Dermatophytes						
<i>Trichophyton rubrum</i>	1	256				
<i>Epidermophyton floccosum</i>	0.5	16				
<i>Microsporum gypseum</i>	1	8				
Permitted range for Amphotericin B control						
0.25 - 1 $\mu\text{g/mL}$.						
0.5 - 2.0 $\mu\text{g/mL}$						
0.25 - 1 $\mu\text{g/mL}$						

- 62 -

Bacteria

Methods

NCCLS-M7-A5 Standard Method - Broth microdilution
 5 (Mueller-Hinton). Inoculum $1-4 \times 10^4$ cfu. Ciprofloxacin test control. Chlorhexidine and cetyl trimethyl ammonium bromide (CTAB) for disinfectant and antiseptic activity comparison.

NCCLS -M7-A5 Standard Method - macrodilution
 10 (Mueller Hinton ± specified enrichments) was also used. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) as 3 log reduction (99.9% kill) at 35°C, 24 hours, aerobically. 48 h titres were not significantly different and are not reported.

15 Micro and macro dilution methods did not give significantly different MIC/MMC.

Table 17

Bacterial strain	$\mu\text{g/mL}$							
	Compound (1)		Ciprofloxacin		Chlorhexidine		CTAB	
Gram positive	MIC	MMC	MIC	MMC	MIC	MMC	MIC	MMC
<i>Staphylococcus aureus</i> ATCC 29213	16	16	0.25	0.25	2	8	16	32
<i>S. aureus</i> - clinical isolate 1	16	16						
<i>S. aureus</i> - clinical isolate 2	16	16						
<i>Enterococcus faecalis</i> ATCC 29212	32	32	0.5	0.5				
<i>E. faecalis</i> - clinical isolate 1	32	32						
<i>E. faecalis</i> - clinical isolate 2	32	32						
<i>Streptococcus pyogenes</i> RMIT	16	16						
<i>Streptococcus pneumoniae</i>	2	2						
<i>Bacillus subtilis</i> RMIT	16	16						
<i>Corynebacterium xerosis</i> RMIT	32	32						
<hr/>								
Gram negative								
<i>Moraxella catarrhalis</i> RMIT	32	32						
<i>Neisseria gonorrhoeae</i>	2	2						
<i>Haemophilus influenzae</i>	0.125	0.125						
<i>Acinetobacter calcoaceticus</i> RMIT	128	256						
<i>Proteus vulgaris</i> RMIT	128	128			6	128	128	256
<i>Proteus mirabilis</i>	256	>512						
<i>Enterobacter aerogenes</i>	512	512						
<i>Klebsiella oxytoca</i>	128	256						

- 63 -

<i>Klebsiella pneumoniae</i>	512	>512							
<i>Escherichia coli</i> ATCC 25922	>512	>512	0.02	0.02	2	4	16	16	
<i>Pseudomonas aeruginosa</i> ATCC 27853	>512	>512	0.25	0.25	32	64	512	>512	
<i>Serratia marcescens</i> RMIT	>512	>512			16	32	128	128	
<i>Bacteroides fragilis</i>	16	32							

Campylobacter

Compound (1) was tested against a range of clinical strains of *Campylobacter* spp. isolated from 5 humans.

Table 18
MIC/MMC (μ g/mL) of Compound (1) by NCCLS - M7 A5 macro dilution test, 42°C, 48 h, microaerophilic incubation

10

		MIC	MMC
<i>Campylobacter jejuni</i> 54/1-2	2	2	
<i>C. jejuni</i> 541-3	2	2	
<i>C. coli</i> 54/2	4	4	
<i>C. foetus</i> 54/3	2	2	
<i>C. hyoilectinalis</i> 54/4	2	2	
<i>C. sputorium</i> 54/5	2	2	
<i>C. laniolis</i> 54/6	2	2	

15 *Campylobacter* is the most common cause of gastroenteritis infection worldwide (bloody diarrhoea, abdominal pain, vomiting, headache, fever, lasting about 1 week). Sequelae are arthritis and Guillain-Barre syndrome(0.1%). It is acquired mainly from eating poultry. Incidence is about 2.5 million persons/year in USA. *C. jejuni* accounts for 99% of cases. It can vary from sub-clinical to severe in compromised patients. It is usually untreated with only fluid replacement or, if the disease is severe or threatening, with antibiotics (Erythromycin, tetracycline or fluoroquinolone).

- 64 -

Table 19
MIC/MFC ($\mu\text{g/mL}$) for Compound (1) (24 h, 35°C, O₂ - micro method)

Bacteria

	MIC	MMC
<i>Neisseria gonorrhoeae</i>	2	2
<i>Haemophilus influenzae</i>	0.125	0.125
<i>Streptococcus pneumoniae</i>	2	2

5

The above are significant human pathogens, all of which have successful treatment regimens with antibiotics.

10 *N. gonorrhoeae* is a cause of vaginitis in women. Compound (1) is thus active at low concentrations against two causes, *Candida albicans* and *N. gonorrhoeae*.

Trichomonas vaginalis

Method

15 The MIC of clinical isolate of *Trichomonas vaginalis* was determined by macrobroth dilution in Diamond's complete medium, modified by Klass (Modified TYM) as described by Garcia, L. Cultures were contained in 5 mL glass, screw-capped bottles without air-spaces. Volumes of 20 5 mL of log 2 dilutions, from 512 $\mu\text{g/mL}$ Compound (1) in 5% DMSO to 0.25 $\mu\text{g/mL}$ Compound (1) in 0.002% DMSO in modified TYM, were inoculated with 0.5 mL volume of cells in log phase of growth giving a final inoculum density of 1×10^4 to 3×10^4 cell/mL. Bottles were incubated aerobically at 25 37°C for 24h before microscopic examination of motility.

30 MIC was determined as the lowest concentration showing no motility. Aliquots of 0.5 mL from all tubes showing no motility were subcultured into further 5 mL volumes of modified TYM and incubated aerobically at 37°C for up to 5 days to confirm non-viability.

Tests were validated by growth controls in TYM, modified TYM with 2.5% DMSO and modified TYM with 5% DMSO.

- 65 -

Tests were performed as 3 replicates on different days.

Results

5

	MIC	MMC
<i>Trichomonas vaginalis</i>	4 µg/mL	4 µg/mL

Example 24 Development of resistance to Compound (1)

10 Selected resistant strains from the 12 week resistance testing were retested simultaneously with parent strains using the new microdilution method.

Table 20

15 Change in MIC ($\mu\text{g/mL}$) of fungal strains after 12 weeks continuous exposure to sub-inhibitory concentrations of Compound (1) in MHB

Test strains	MIC $\mu\text{g/mL}$	
	M38-P	
	Initial	Final
<i>Rhodotorula rubra</i>	8	16
<i>Aspergillus fumigatus</i>	8	8
<i>Rhizopus stolonifer</i>	4	16
<i>Fusarium graminearum</i>	4	4

20 Fungi exhibit up to a four-fold difference in MIC on repeat testing. Significant increases in MIC are ≥ 8 - fold.

There is no significant development of resistance by the filamentous mould strains tested.

25 Example 25 Effect of formulation in ethanol on activity

The effect of formulation in DMSO and ethanol on the MIC of Compound (1) was compared for *Candida albicans*,

- 66 -

Salmonella Typhimurium and *Escherichia coli* using both the macrodilution and microdilution tests.

Stock solutions in ethanol were allowed to stand for 48 h before use to improve solubility. Compound (1) is 5 not as soluble in ethanol as in DMSO. The concentration of ethanol and DMSO was kept constant at 2% and compared to a decreasing concentration of solvent on normal dilution of the stock solution. There was no difference between the two test methods. There was no difference in MIC between 10 constant and decreasing levels of DMSO. Only *E. coli* showed an enhanced susceptibility to ethanol in the presence of a constant 2% ethanol.

Table 21

15 **Effect of solvent on MIC ($\mu\text{g/mL}$) of Compound (1) using
microdilution**

	DMSO		EtOH (2%)	
	MIC	MBC	MIC	MBC
<i>Escherichia coli</i>	512	>512	128	256
<i>Salmonella Typhimurium</i>	512	>512	512	>512
<i>Candida albicans</i>	8	16	8	16

The synergistic effect of ethanol on *E. coli* was noted previously when solvents were being tested for 20 selection of an appropriate solvent for the drug. Ethanol has no enhancing effect on *Staphylococcus*, *Salmonella* or *Candida*. DMSO is a better solvent for the drug in in-vitro tests. Ethanol will be used for animal studies.

25 **Example 26 Stability of Compound (1) solutions on
storage**

Stock solutions of Compound (1) at 512 $\mu\text{g/mL}$ in water + 5% DMSO were stored at room temperature (RT ~ 18 - 30 21°C), 4°C and -20°C for up to 12 weeks and the potency tested by measurement of MIC for *Bacillus subtilis* at 2-weekly intervals.

- 67 -

Table 22

**Stability of Compound (1) stock solutions at 512 µg/mL
tested by measurement of the MIC/MBC for *Bacillus subtilis***
5 **(24h, 35°C) at 2 weekly intervals**

Test time	RT ₁		4°C		-20°C ₂	
	MIC	MBC	MIC	MBC	MIC	MBC
0	4	8	4	8	4	8
2	4	8	4	8	4	8
4	4	8	4	16	4	16
6	4	16	4	16	4	16
8	8	16	4	16	4	16
10	8	16	4	16	4	16
12	8	16	4	16	4	16

1 1 Solution changed from light yellow to dark yellow
 after 8 weeks.

10 2 Solution changed from light yellow to dark yellow
 after 2 weeks.

Compound (1) is very stable, dilute solutions retaining potency for 12 weeks on storage at 4°C and -20°C.
15 Twofold loss of potency at room temperature after 6 weeks is very low compared to working solutions of antibiotics. It is also within the allowed variation range for MIC measurements for bacteria (2-fold). Control antifungals were not tested.

20 Example 27 Effect of Compound (1) on growth of the human malaria parasite, *Plasmodium falciparum*, in human red blood cells *in vitro*

25 The aim of this example was to quantify the effect of Compound (1) on invasion and growth of the human malaria parasite *Plasmodium falciparum* in human red blood cells *in vitro*.

Methods**Malaria Parasites**

3D7 is a well characterised *in vitro* culture-adapted line of *P. falciparum* that was used for these experiments. The parasite undergoes repeating cycles of growth and replication within human red blood cells. The duration of each complete cycle is 48 hours, beginning with young ring-stage parasites which mature through pigmented trophozoites during the first 24 hours of the cycle to segmented schizonts which burst to release infectious merozoites which rapidly invade red blood cells. Newly invaded merozoites become ring forms, and the cycle continues.

15 **Parasite culture and growth inhibition assays**

P. falciparum parasites were maintained in synchronous *in vitro* culture in freshly collected human red blood cells, using well-established techniques. For invasion assays, red blood cells containing stage-synchronized mature, pigmented trophozoites were purified and resuspended in fresh human red blood cells, so that approximately two in every 100 red blood cells was parasitised (2% parasitaemia). Fresh culture media was added to give a final red blood cell concentration of 2×10^8 red cells/ml.

Aliquots of the red blood cell suspension containing either the test compound, the vehicle alone (in this case EtOH) or PBS (control) were incubated at 37°C in an atmosphere of reduced oxygen tension (1% O₂, 3% CO₂, 30 96% N₂). Thin blood smears were made immediately (time = 0) then subsequently after 24, 48 and 72 hours of culture. For each smear, parasitaemia and stage of parasite maturation was quantified by microscopic examination after staining with Giemsa at pH 7.2. This allowed invasion, parasite development and subsequent re-invasion to be quantified. At 35 each sampling time point, the culture medium (\pm compound/vehicle) in all samples was completely replaced

- 69 -

with fresh medium.

Compound (1) was tested as aqueous solutions of 100, 400 and 1000 μ g/ml each containing 10% EtOH. Stock solutions were stored at 4°C until required. For the 5 assay, each solution was further diluted 1:40 in complete parasite culture medium (pH 7.2) to the desired working concentration (5, 10 and 25 μ g/ml), then sterile filtered (0.22 μ m) before being added to the parasitised red blood cell suspension. Stock solutions were stored at 4°C 10 throughout the duration of the assay, and diluted appropriately in parasite culture medium when required. It should be noted that at 1000 μ g/ml, the compound was incompletely soluble, even after warming to 37°C and vigorous vortexing. Thus the tests performed at a putative 15 concentration of 25 μ g/ml, may in fact have been performed at a lower effective concentration.

Results

The effect of Compound (1) on parasite growth was 20 tested at final concentrations of 5, 10 and 25 μ g/ml. Results are presented graphically in Figure 2. A concentration-dependent inhibitory effect on parasite growth and replication was detected at all concentrations of drug tested, being greatest at the highest concentration 25 tested (25 μ g/ml) after 72 hours of culture. EtOH alone, at a final concentration of 0.25% had no significant effect on parasite growth. All concentrations of the compound tested showed no detectable adverse effect on red blood cell morphology.

At 25 μ g/mL no parasites were observed and at 30 10 μ g/mL only very few were found, suggesting that the compound actually killed the parasites.

It will be apparent to the person skilled in the art that while the invention has been described in some 35 detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing

- 70 -

from the scope of the inventive concept disclosed in this specification.

References cited herein are listed on the following pages, and are incorporated herein by this
5 reference.

REFERENCES

Burton, H., Duffield, G., *J. Chem. Soc.*, 1949, 78

5 Denisenko P.P., Tarasenko A.A., Russian patent No. 2145215,
"Substances having antimicrobial, antifungal, antiprotozoal
activity" published 10th February 2000

Foyer, G., *Chemistry of nitro and nitroso groups*, Moscow,
10 1973, Pt.2, pp.194-195

Garcia, L., Parasite culture: *Trichomonas vaginalis*,
Clinical Microbiology Procedures Handbook, H. D. Isenberg
(ed.), volume 2, American Society for Microbiology,
15 Washington, USA, 7.9.3.1-7.9.3.6.

Hamlin, K., Weston, A., *J. Am. Chem. Soc.* 71, 2210 (1949)

Knoevenagel, E., Walter, L., *Ber.*, 37, 4502 (1904)

20 Kuna P., *Chemical radiation protection*, Moscow, 1989,
pp.25-28

Mashkovskiy M.D., *Clinical agents*, Pt.2, Moscow, 1986,
25 p.189

Perekalkin V.V., *Unlimited nitrocompounds*, Leningrad, 1982,
pp.55, 59, 61, 71, 73, 88, 89, 91, 95

30 Perekalkin V.V., *Unlimited nitrocompounds*, Leningrad, 1982,
p.67

Perekalkin V.V., *Unlimited nitrocompounds*, Moscow, 1966,
p.119


35 Vladimirov V.G. et al., *Radiation protectors, structure and
operation*, Kiev, 1989, p.139

- 72 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering
5 an effective amount of a compound of formula I:

10



in which

X and Y are either the same or different and selected from a heteroatom;

15

is a double or single bond depending on the heteroatoms X and Y;

R₁ to R₅ are either the same or different and selected from hydrogen or a non-deleterious substituent; and

20

R₆ and R₇ are either the same or different and selected from hydrogen and a non-deleterious substituent or one of R₆ and R₇ are absent when there is a double bond present,

pharmaceutically acceptable salts or derivatives, 25 pro-drugs, tautomers and/or isomers thereof.

2. A method according to claim 1, in which the microbial infection is a bacterial infection, fungal infection, yeast infection, protozoal infection or viral infection.

3. A method according to claim 1 or claim 2, in which the bacterial infection is caused by a Gram Positive or Gram Negative bacterium.

35

4. A method according to claim 3, in which the Gram

- 73 -

Positive or Gram negative bacterium is *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumonia*, *Salmonella typhimurium* or *pseudotuberculosis*, *Acinetobacteria*, *Pseudomonas aeruginosa*, *Clostridium perfringens*, *Clostridium difficile*, *Campylobacter jejuni* or *Bacteroides fragilis*.

5. A method according to claim 1 or claim 2, in which the fungal or yeast infection is *Trichophyton interdigitale*, *Aspergillus fumigatus* or *Candida albicans*.

10 6. A method according to claim 1 or claim 2, in which the protozoal infection is *Plasmodium falciparum* or *Trichomonas vaginalis*.

15 7. A method according to any one of claims 1 to 6, in which the microbial infection is a bacterial or fungal wound infection, mucosal infection, enteric infection, septic condition, pneumonia, trachoma, ornithosis, trichomoniasis or salmonellosis.

20 8. A method according to any one of claims 1 to 7, in which X and Y are either the same or different and selected from O and N.

25 9. A method according to claim 8, in which X and Y are both O.

10. A method according to any one of claims 1 to 9, 30 in which R₁ and R₂ are either the same or different and selected from hydrogen, hydroxy, halogen or optionally substituted C₁₋₆ alkyl.

11. A method according to any one of claims 1 to 10, 35 in which R₃ to R₅ are either the same or different and selected from hydrogen, hydroxy, halogen, nitro, C₁₋₆ alkoxy or optionally substituted C₁₋₆ alkyl.

- 74 -


12. A method according to claim 10 or claim 11, in which halogen is chlorine or bromine.

5 13. A method according to any one of claims 1 to 12, in which the compound of the formula I is in the form of the E isomer.

10 14. A method according to any one of claims 1 to 13, in which X, Y, ~~Z~~, R₆ and R₇ are as defined in claim 1; R₁ and R₂ are either the same or different and selected from hydrogen, hydroxy, Cl, Br and C₁₋₄ alkyl; and R₃ to R₅ are either the same or different and selected from hydrogen, hydroxy, Cl, Br, nitro, C₁₋₄ alkoxy or C₁₋₄ alkyl.

15 15. A method according to any one of claims 2 to 14, in which X and Y are O, R₁ is methyl and R₂ and R₃ are hydrogen (3,4-methylenedioxy-β-methyl-β-nitrostyrene)


20



1

25 25 X and Y are O and R₁ to R₃ are hydrogen (3,4-methylenedioxy-β-nitrostyrene)


30



2

X is N, Y is NH, R₁ is methyl and R₂ and R₃ are hydrogen (benzimidazole-5-β-nitropropylene)

35




- 75 -

3

X is N, Y is NH, R₁ is hydrogen, R₂ is methyl and R₃ is absent . (2-methyl benzimidazole-5-β-nitroethylene)

5




4

10

X is O, Y is N, R₁ and R₂ are hydrogen and R₃ is absent (benzoxazole-5-β-nitroethylene)


15



5

20

X is N, Y is O, R₁ and R₂ are methyl and R₃ is absent (2-methyl benzoxazole-5-β-nitropropylene)



25

6

16. Use of the compound of formula I as defined in claim 1 in the manufacture of a medicament for the treatment and/or prophylaxis of a microbial infection.

30

17. Use of the compound of formula I as defined in claim 1 for the treatment and/or prophylaxis of a microbial infection.

35

18. A method for protecting a subject from radiation damage which comprises administering an effective amount of the compound of formula I as defined in claim 1 to a

- 76 -

subject in need thereof.

19. A method according to claim 18, in which the radiation is ionising radiation.


5

20. A method of cancer radiotherapy which comprises administering to a subject in need of such therapy an effective amount of the compound of formula I as defined in claim 1 and subjecting the locus of a tumour in the subject 10 to a radiation source.

21. Use of the compound of formula I as defined in claim 1 as an antimicrobial or radioprotective agent.

15 22. A compound of formula Ia:

20



Ia

in which


X, Y, ~~and R₁~~ to R₇ are as defined in formula I
25 above,

with the provisos that when both X and Y are O and R₂ to R₇ are hydrogen, then R₁ is not hydrogen, C₁₋₄ alkyl or CO₂Et or when both X and Y are O, then R₁ to R₇ are not hydrogen.

30

23. A process for the preparation of the compound of formula Ia defined above which comprises condensing a compound of formula II:

35



- 77 -

II

in which X, Y, R₃ to R₇ are as defined in formula Ia in claim 22

with a compound of formula III:

5




III

in which R₁ and R₂ are as defined in formula Ia in claim 22.

10

24. A process for the preparation of the compound of formula Ia defined in claim 22 which comprises reacting a compound of formula IV:

15



20

IV

in which X, Y, R₁ to R₇ are as defined in formula Ia in claim 22 with C(NO₃)₄.

25

25. A process according to claim 23 or claim 24 which is performed in the presence of a catalyst.

30

26. A pharmaceutical or veterinary composition comprising the compound of formula Ia defined in claim 22 together with a pharmaceutically or veterinarily acceptable carrier.

27. A composition according to claim 26 which is a topical, oral or parenteral composition.

35

28. A composition according to claim 26 or claim 27 in which the pharmaceutically or veterinarily acceptable

- 78 -

carrier is an organic solvent.

29. A composition according to claim 28 in which the
organic solvent is acetone, benzene, acetonitrile, DMSO or
5 an alcohol.

AMENDED CLAIMS

[received by the International Bureau on 16 October 2002 (16.10.02);
original claims 1-29 replaced by amended claims 1-31

carrier is an organic solvent.

29. A composition according to claim 28 in which the
organic solvent is acetone, benzene, acetonitrile, DMSO or
5 an alcohol.

30. A method according to any one of claims 1 to 15,
in which the method of treatment and/or prophylaxis occurs
in vivo.

10

31. A method according to any one of claims 1 to 15
or 30, in which the microbial infection is caused by a
resistant microbial species.

15

1/2




Figure 1

2/2





Figure 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00783

A. CLASSIFICATION OF SUBJECT MATTER																						
Int. Cl. ⁷ : C07D 317/52, 317/50, 263/56; A61K 31/36, 31/4184; A61P 31/00, 31/04, 31/06, 31/08, 31/10, 39/00																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols)																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Substructure based on 3,4 methylenedioxy, benzoxazole and benzimidazole nitrostyrene analogs for STN, Chemical Abstracts, WPIDS.																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	Kodukulla, R.P.K. <i>et al</i> , Synthetic Communications (1994), 24(6), pages 819 to 832. "Synthesis, chemical transformation and antimicrobial activity of a novel class of nitroolefins: 1,3-diaryl-2-nitroprop-1-enes". Compounds 2(g) and 4(g) and Table 2, CA Registry number: 1485-00-3.	1 to 3, 5, 8, 9, 11, 13, 16, 17, 22, 23, 26 to 29																				
X	US 4469703 B (Kis-Tamas, A. <i>et al</i>) 4 September 1984. Column 6, lines 39 to 59; Tables I and II; Examples 11 and 12; Example 38 in Table IV.	1, 2, 4, 7, 8, 9, 11, 13, 16, 17, 21, 22, 23, 26, 27, 28, 29																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex																				
<p>* Special categories of cited documents:</p> <table> <tbody> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </tbody> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 16 July 2002	Date of mailing of the international search report 16 AUG 2002																					
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer  D.A. LALLY Telephone No : (02) 6283 2533																					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00783

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Parker, M.A. <i>et al</i> , Journal of Medicinal Chemistry, (1998), 41(6), pages 1001 to 1005. "Synthesis and Pharmacological Evaluation of Ring-Methylated Derivatives of 3,4-(Methylenedioxy) amphetamine (MDA)". Compounds 6 (a to c), CA Registry numbers: 204916-88-1, 204916-92-7, 204916-93-8.	22, 23
X	Clark, C.R. <i>et al</i> , Journal of Chromatographic Science (1996), 34 (1), pages 34 to 42. "Analysis of 1-(3-methoxy-4,5-methylenedioxyphenyl)-2-propanamine (MMDA) derivatives synthesised from nutmeg oil and 3-methoxy-4,5-methylenedioxybenzaldehyde". Scheme 4, CA Registry numbers: 15896-78-3, 17055-07-1, 172518-53-5.	22, 23
X	Nichols, D.E. <i>et al</i> , Journal of Medicinal Chemistry (1979), 22(10), pages 1264 to 1267. "Steric effects of substituents on phenylethylamine hallucinogens. 3,4-(Methylenedioxy) amphetamine analogs alkylated on the dioxole ring". Compounds 9 and 10, CA Registry numbers: 71203-55-9, 71203-58-2.	22, 23
X	Shulgin, A.T., Canadian Journal of Chemistry (1968), 46(1), pages 75 to 77. "Convenient synthesis of myristicinaldehyde". Compound 4 and apiolealdehyde analog, CA Registry numbers: 17055-07-1, 18989-89-4, 18989-90-7.	22, 23
X	WO 00 15599 A (ABBOTT LABORATORIES) 23 March 2000. Example 3.	22, 23
X	WO 98 25917 A (ABBOTT LABORATORIES) 18 June 1998. Scheme 1, compound 4.	22, 23
X	WO 97 30046 A (ABBOTT LABORATORIES) 21 August 1997. Scheme I, compound 2; Scheme II, compound 27; Example 15A.	22, 23
P,X	US 6329536 B (Ji, J. <i>et al</i>) 11 December 2001. Example 3.	22, 23
X	Chem Abs Reg #'s 107092-58-0, 109258-02-8, 1211-65-0, 1215-58-3, 124201-30-5, 132151-78-1, 13326-78-8, 134040-37-2, 138698-29-0, 1485-00-3, 151560-57-5, 151560-66-6, 15794-43-1, 15794-47-5, 15896-78-3, 17055-07-1, 172518-53-5, 189162-42-3, 18989-89-4, 18989-90-7, 204916-88-1, 204916-92-7, 204916-93-8, 212332-76-8, 21461-33-6, 22568-48-5, 22959-13-3, 22959-14-4, 22959-17-7, 27164-14-3, 33036-23-6, 37162-74-6, 37629-56-4, 43017-82-9, 49571-78-0, 49571-79-1, 49711-31-1, 50882-25-2, 5438-41-5, 58532-37-9, 61675-23-8, 63141-48-0, 65762-51-8, 66425-16-9, 67370-05-2, 67370-10-9, 67708-69-4, 71203-55-9, 71203-58-2, 77834-77-6, 79743-86-5, 82040-72-0, 82040-73-1, 87091-27-8, 88484-87-1, 97383-34-1	22 to 24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00783

Error! Hyperlink reference not valid.

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	200015599	EP	114022	US	6329536		
WO	9822791	AU	48819/97	IL	119622	IL	135888
		JP	2001504722	JP	20011224565	US	6246903
WO	9730046	AU	22678/97	AU	78263/98	BG	103986
		BR	9707394	BR	9810031	CN	1079397
		CN	1215401	CN	1265097	CZ	9802536
		EP	888340	EP	991620	HU	9902316
		HU	200002681	IL	125453	IL	132615
		JP	2000504727	NO	996244	NZ	331124
		NZ	503383	SK	1706/99	US	6124341
		WO	9857933	ZA	9701184	ZA	9805209
US	6329536	EP	1114022	WO	200015599		

END OF ANNEX